ProShare Advisors
TGTX icon

ProShare Advisors’s TG Therapeutics TGTX Stock Holding History

ProShare Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.13M Sell
20,601
-1,899
-8% -$77.7K ﹤0.01% 767
2026
Q1 		$747K Sell
22,500
-5,630
-20% -$168K ﹤0.01% 887
2025
Q4 		$839K Buy
28,130
+936
+3% +$30.6K ﹤0.01% 877
2025
Q3 		$982K Sell
27,194
-5,051
-16% -$166K ﹤0.01% 814
2025
Q2 		$1.16M Sell
32,245
-516
-2% -$19.2K ﹤0.01% 772
2025
Q1 		$1.29M Sell
32,761
-9,194
-22% -$309K ﹤0.01% 749
2024
Q4 		$1.26M Buy
41,955
+12,951
+45% +$372K ﹤0.01% 827
2024
Q3 		$678K Buy
29,004
+10,429
+56% +$228K ﹤0.01% 961
2024
Q2 		$330K Sell
18,575
-6,339
-25% -$101K ﹤0.01% 1219
2024
Q1 		$379K Buy
24,914
+1,961
+9% +$31.2K ﹤0.01% 1265
2023
Q4 		$392K Buy
22,953
+5,127
+29% +$59.6K ﹤0.01% 1199
2023
Q3 		$149K Sell
17,826
-21
-0.1% -$293 ﹤0.01% 1552
2023
Q2 		$443K Buy
17,847
+2,171
+14% +$56.1K ﹤0.01% 1021
2023
Q1 		$236K Sell
15,676
-1,453
-8% -$22.1K ﹤0.01% 1355
2022
Q4 		$203K Buy
17,129
+2,443
+17% +$17.7K ﹤0.01% 1494
2022
Q3 		$87K Sell
14,686
-277
-2% -$1.82K ﹤0.01% 1590
2022
Q2 		$64K Sell
14,963
-9,332
-38% -$58.3K ﹤0.01% 1672
2022
Q1 		$231K Sell
24,295
-4,002
-14% -$46.3K ﹤0.01% 1797
2021
Q4 		$537K Buy
28,297
+11,869
+72% +$308K ﹤0.01% 1390
2021
Q3 		$547K Sell
16,428
-16,828
-51% -$521K ﹤0.01% 1151
2021
Q2 		$1.29M Buy
33,256
+711
+2% +$27.9K ﹤0.01% 896
2021
Q1 		$1.57M Buy
32,545
+7,007
+27% +$337K ﹤0.01% 778
2020
Q4 		$1.33M Buy
25,538
+11,925
+88% +$403K ﹤0.01% 765
2020
Q3 		$364K Buy
13,613
+485
+4% +$11.2K ﹤0.01% 1074
2020
Q2 		$256K Buy
+13,128
New +$211K ﹤0.01% 1321
2020
Q1 		– Sell
-11,682
Closed -$130K – 1546
2019
Q4 		$130K Buy
+11,682
New +$88.8K ﹤0.01% 1662
2014
Q3 		– Sell
-11,442
Closed -$107K – 2353
2014
Q2 		$107K Sell
11,442
-4,296
-27% -$27.5K ﹤0.01% 2342
2014
Q1 		$109K Buy
+15,738
New +$93.1K ﹤0.01% 2676

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

ProShare Advisors's TGTX Position: Q2 2026 in Review

ProShare Advisors reduced its TG Therapeutics (TGTX) stake by 8.4% in Q2 2026, selling an estimated $77.7K and leaving 20,601 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #767.

ProShare Advisors first reported a position in TGTX in Q1 2014 and has held it in 28 quarters since. The position peaked at $1.57M in Q1 2021. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • ProShare Advisors held 20,601 shares of TG Therapeutics worth $1.13M as of Q2 2026.
  • ProShare Advisors sold 1,899 TG Therapeutics shares in Q2 2026, an estimated $77.7K.
  • TG Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #767 holding.
  • ProShare Advisors first reported a position in TG Therapeutics in Q1 2014 and has held it in 28 quarters since.
  • ProShare Advisors's TG Therapeutics position peaked at $1.57M in Q1 2021.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.